Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$42.57 USD

42.57
740,451

-0.06 (-0.14%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $42.57 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (172 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Edwards Lifesciences (EW) Stock

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.

New Strong Buy Stocks for February 2nd

by Zacks Equity Research

CVX, PSX, UMC, AMN, and GPRO have been added to the Zacks Rank #1 (Strong Buy) List on February 2, 2022.

PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) fourth-quarter results benefit from solid performance at Discover & Analytics Solutions business.

Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up

by Zacks Equity Research

Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business. However, forex woes persist.

Premier, Inc. (PINC) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 10.61% and 8.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal second-quarter results are likely to reflect solid performance in the Pharmaceutical segment.

Diagnostics Sales to Drive Hologic's (HOLX) Q1 Earnings

by Zacks Equity Research

Strength in the Diagnostics division is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.

New Strong Buy Stocks for January 31st

by Zacks Equity Research

ADM, MSBI, USAK, WHR, and AMN have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2022.

AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, AMN Healthcare Services (AMN) closed at $99.51, marking a +0.35% move from the previous day.

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.

Stryker (SYK) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.

ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates

by Zacks Equity Research

ResMed's (RMD) Q2 earnings meet estimates, with robust demand for sleep and respiratory care devices driving the top line.

McKesson (MCK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.

Abiomed (ABMD) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q3 sales.

AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

CONMED's (CNMD) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

CONMED's (CNMD) fourth-quarter earnings reflect strong segmental performance.

Accuray (ARAY) Q2 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Accuray (ARAY) registers growth in Products revenues during fiscal Q2, thereby partly driving its overall top line.

NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View

by Zacks Equity Research

NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strength in both of its revenue sources.

Align Technology (ALGN) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Robust scanner shipments and an increase in Invisalign volumes within the teen segment are expected to have contributed to Align Technology's (ALGN) Q4 performance.

IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Strong organic recurring revenue growth in the CAG diagnostics business and rise in new instrument placements are likely to have contributed to IDEXX's (IDXX) Q4 revenues.

Best Value Stocks to Buy for January 27th

by Zacks Equity Research

UMC, AMN, and FNB made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 27, 2022

New Strong Buy Stocks for January 27th

by Zacks Equity Research

AMN, UMC, MRTN, FNB, and SLB have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2022.